Research programme: BACE1 protein inhibitors - Astellas Pharma/CoMentis

Drug Profile

Research programme: BACE1 protein inhibitors - Astellas Pharma/CoMentis

Alternative Names: BACE inhibitors - CoMentis; Disease modifying Alzheimer's disease therapy - CoMentis; OM 991; OM 992

Latest Information Update: 21 Oct 2014

Price : $50

At a glance

  • Originator CoMentis
  • Class Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 16 Oct 2014 Astellas Pharma exercises option to terminate its collaboration agreement with CoMentis
  • 25 Apr 2008 Astellas Pharma and CoMentis have entered into an exclusive worldwide collaboration agreement to develop and commercialise products from CoMentis' β-secretase inhibitor programme
  • 23 Jul 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top